Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Schilder RJ, et al. Among authors: lankes ha. Gynecol Oncol. 2012 Oct;127(1):70-4. doi: 10.1016/j.ygyno.2012.06.009. Epub 2012 Jun 16. Gynecol Oncol. 2012. PMID: 22710075 Free PMC article. Clinical Trial.
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.
Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Farley J, et al. Among authors: lankes ha. Gynecol Oncol. 2011 May 1;121(2):303-8. doi: 10.1016/j.ygyno.2011.01.030. Epub 2011 Feb 16. Gynecol Oncol. 2011. PMID: 21329967 Free PMC article. Clinical Trial.
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM, Fischer EG, Leslie KK. Garcia AA, et al. Among authors: lankes ha. Gynecol Oncol. 2012 Mar;124(3):569-74. doi: 10.1016/j.ygyno.2011.10.022. Epub 2011 Oct 28. Gynecol Oncol. 2012. PMID: 22037316 Free PMC article. Clinical Trial.
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB. Gold MA, et al. Among authors: lankes ha. Gynecol Oncol. 2012 Jun;125(3):635-9. doi: 10.1016/j.ygyno.2012.03.023. Epub 2012 Mar 22. Gynecol Oncol. 2012. PMID: 22446624 Free PMC article. Clinical Trial.
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Leslie KK, et al. Among authors: lankes ha. Gynecol Oncol. 2012 Nov;127(2):345-50. doi: 10.1016/j.ygyno.2012.07.127. Epub 2012 Aug 7. Gynecol Oncol. 2012. PMID: 22885469 Free PMC article. Clinical Trial.
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. Coleman RL, et al. Among authors: lankes ha. Gynecol Oncol. 2012 Dec;127(3):538-43. doi: 10.1016/j.ygyno.2012.08.020. Epub 2012 Aug 23. Gynecol Oncol. 2012. PMID: 22922531 Free PMC article. Clinical Trial.
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Farley J, et al. Among authors: lankes ha. Lancet Oncol. 2013 Feb;14(2):134-40. doi: 10.1016/S1470-2045(12)70572-7. Epub 2012 Dec 21. Lancet Oncol. 2013. PMID: 23261356 Free PMC article. Clinical Trial.
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. Schilder RJ, et al. Among authors: lankes ha. Gynecol Oncol. 2013 Apr;129(1):86-91. doi: 10.1016/j.ygyno.2013.01.006. Epub 2013 Jan 13. Gynecol Oncol. 2013. PMID: 23321064 Free PMC article. Clinical Trial.
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. Powell MA, et al. Among authors: lankes ha. Gynecol Oncol. 2014 Oct;135(1):38-43. doi: 10.1016/j.ygyno.2014.07.083. Epub 2014 Jul 11. Gynecol Oncol. 2014. PMID: 25019571 Free PMC article. Clinical Trial.
68 results